[Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].
Antiangiogenic drugs
Bevacizumab
Expert consensus
Radioactive brain necrosis
Journal
Zhongguo fei ai za zhi = Chinese journal of lung cancer
ISSN: 1999-6187
Titre abrégé: Zhongguo Fei Ai Za Zhi
Pays: China
ID NLM: 101126433
Informations de publication
Date de publication:
20 May 2022
20 May 2022
Historique:
pubmed:
16
5
2022
medline:
25
5
2022
entrez:
15
5
2022
Statut:
ppublish
Résumé
Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
. 【中文题目：抗血管药物治疗放射性脑坏死专家共识】 【中文摘要：血管内皮生长因子（vascular endothelial growth factor, VEGF）的高水平表达是放射性脑坏死（cerebral radiation necrosis, CRN）发生的重要机制。抗血管生成药物（贝伐珠单抗）通过抑制VEGF，作用于脑坏死区域周围的血管组织，减轻CRN引起的脑水肿。许多研究证实贝伐珠单抗可有效缓解脑坏死症状，改善患者的体力状况评分以及减轻影像学上脑水肿范围。抗血管治疗的疗效主要与药物作用时长相关，低剂量抗血管药物即可达到较好的治疗效果。预防是最好的治疗，CRN的发生与肿瘤相关因素和治疗相关因素相关，通过控制两方面因素，可有效预防CRN。
】 【中文关键词：放射性脑坏死；抗血管生成药物；贝伐珠单抗；专家共识】.
Autres résumés
Type: Publisher
(chi)
【中文题目：抗血管药物治疗放射性脑坏死专家共识】 【中文摘要：血管内皮生长因子（vascular endothelial growth factor, VEGF）的高水平表达是放射性脑坏死（cerebral radiation necrosis, CRN）发生的重要机制。抗血管生成药物（贝伐珠单抗）通过抑制VEGF，作用于脑坏死区域周围的血管组织，减轻CRN引起的脑水肿。许多研究证实贝伐珠单抗可有效缓解脑坏死症状，改善患者的体力状况评分以及减轻影像学上脑水肿范围。抗血管治疗的疗效主要与药物作用时长相关，低剂量抗血管药物即可达到较好的治疗效果。预防是最好的治疗，CRN的发生与肿瘤相关因素和治疗相关因素相关，通过控制两方面因素，可有效预防CRN。
】 【中文关键词：放射性脑坏死；抗血管生成药物；贝伐珠单抗；专家共识】.
Identifiants
pubmed: 35570144
doi: 10.3779/j.issn.1009-3419.2022.101.18
pmc: PMC9127755
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
chi
Sous-ensembles de citation
IM
Pagination
291-294Références
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):499-508
pubmed: 16517093
Ann Palliat Med. 2021 Feb;10(2):2018-2026
pubmed: 33549015
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):996-1001
pubmed: 19783374
Childs Nerv Syst. 2019 Nov;35(11):2043-2046
pubmed: 31367784
Onco Targets Ther. 2019 Oct 11;12:8447-8453
pubmed: 31632089
J Neurooncol. 2018 Sep;139(2):421-429
pubmed: 29696531
J Clin Med Res. 2017 Apr;9(4):273-280
pubmed: 28270886
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1060-1069
pubmed: 27742540
J Neurooncol. 2014 Aug;119(1):101-9
pubmed: 24789256
Curr Oncol Rep. 2019 Jun 19;21(8):66
pubmed: 31218455
Oxid Med Cell Longev. 2021 Dec 24;2021:4793517
pubmed: 34976300
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95
pubmed: 20399573
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Oncotarget. 2016 Feb 16;7(7):7773-9
pubmed: 26675376
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1087-1095
pubmed: 29885994
Strahlenther Onkol. 2019 Mar;195(3):277-280
pubmed: 30689030
Neurooncol Pract. 2016 Dec;3(4):272-280
pubmed: 27833757
Front Oncol. 2020 Feb 11;10:12
pubmed: 32117704
J Natl Cancer Inst. 2019 Jun 1;111(6):620-628
pubmed: 30299488
Mol Cancer. 2019 Feb 7;18(1):21
pubmed: 30732625
J Neurosurg. 2016 Jul;125(1):17-23
pubmed: 26544782
Int J Radiat Oncol Biol Phys. 1981 Feb;7(2):243-52
pubmed: 6260715
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):419-24
pubmed: 16226848
Case Rep Oncol. 2013 Dec 07;6(3):598-601
pubmed: 24474923
Front Oncol. 2021 Sep 28;11:746941
pubmed: 34650930
Cochrane Database Syst Rev. 2018 Jul 09;7:CD011492
pubmed: 29987845
Recent Pat Anticancer Drug Discov. 2017;12(3):272-277
pubmed: 28443515
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6
pubmed: 17236958
Melanoma Res. 2016 Aug;26(4):387-94
pubmed: 27223498
Radiother Oncol. 2018 Mar;126(3):511-518
pubmed: 29398153